telcagepant (MK-0974)
Jump to navigation
Jump to search
Introduction
FDA approval pending (2009)
* On July 2011, Merck announced that it had discontinued development of telcagepan[2]
Indications
Dosage
- 150 mg or 300 mg PO
Mechanism of action
- calcitonin gene-related peptide receptor antagonist
- lacks vasoconstrictor effects of triptans
More general terms
References
- ↑ Ho TW et al, Efficacy and tolerability of MK-0974 (telcagepant) a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel treatment trial. Lancet 2008, 372:2115 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19036425
Edvinsson L CGRP-receptor antagonism in migraine treatment. Lancet 2008, 372:2089 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19036426 - ↑ 2.0 2.1 Wikipedia: Telcagepant https://en.wikipedia.org/wiki/Telcagepant
- ↑ 3.0 3.1 New Drug Approvals. Telcagepant Revisited. 2017 https://newdrugapprovals.org/2017/01/25/telcagepant-revisited/